Transducers can be divided in:
1.) Transducers where the sound wave is transmitted and received by different elements.
2.) Transducers where multiple elements part of the time transmit and part of the time receive sound energy.
The first type of ultrasound transducer is used in detection of blood flow (also called nonimaging transducers). For example, the continuous wave transducer (Pedoff transducer) has two separate elements, where one element is always transmitting while the other element is always receiving.
Probes of the second type are used to image cardiac structures and have the capability to use various Doppler techniques to detect blood flow (also called imaging transducers). For example, continuous wave, pulsed wave, high pulse repetition frequency, color flow, M-mode, and 2D-mode are the various modes that this type of transducer can perform.

Transducers can also be divided in mechanical and electronic or phased scan types.
Mechanical transducers use a combination of single element oscillation, multiple element rotation, or a single element and set of acoustic mirrors to generate the sweeping beam for 2D mode. Caused by the vibration (created as the mirrors rotate or oscillate inside the cover) is this type sometimes called the 'wobbler'. Mechanical transducers are cheaper than electronic transducers.
Different types of electronic or phased array probes can create a linear or rectangular shaped scan plane as well as a sector or pie shaped scan plane. Sector scanners are most useful for cardiac ultrasound examinations where the beam is directed between the ribs to image the heart. A linear array transducer is more useful in abdominal, OB/GYN, and small parts examinations. Electronic transducers are more expensive but they provide dynamic focusing and smaller probe.

See also Rectangular Array Transducer.

(UCA / USCA) Ultrasonography is the most commonly performed diagnostic imaging procedure. The introduction of sonographic contrast media into routine practice modifies the use of ultrasound in a variety of clinical applications. USCAs consist of microbubbles filled with air or gases and can be classified according to their pharmacokinetics. Among the blood pool agents, transpulmonary ultrasound contrast agents offer higher diagnostic potential compared to agents that cannot pass the pulmonary capillary bed after a peripheral intravenous injection. In addition to their vascular phase, some USCAs can exhibit a tissue- or organ-specific phase.
The sonogram image quality is improved either by decreasing the reflectivity of the undesired interfaces or by increasing the backscattered echoes from the desired regions.

Different types of ultrasound contrast agents:
Ultrasound contrast agents act as echo-enhancers, because of the high different acoustic impedance at the interface between gas and blood. The enhanced echo intensity is proportional to the change in acoustical impedance as the sound beam crosses from the blood to the gas in the bubbles.

The ideal qualities of an ultrasound contrast agent:
A typical ultrasound contrast agent consists of a thin flexible or rigid shell composed of albumin, lipid, or polymer confining a gas such as nitrogen, or a perfluorocarbon. The choice of the microbubble shell and gas has an important influence on the properties of the agent.
Current generations of microbubbles have a diameter from 1 μm to 5 μm. The success of these agents is mostly dependent on the small size and on the stability of their shell, which allows passage of the microbubbles through the pulmonary circulation. Microbubbles must be made smaller than the diameter of capillaries or they would embolize and be ineffective and perhaps even dangerous.
The reflectivity of these microbubbles is proportional to the fourth power of a particle diameter but also directly proportional to the concentration of the contrast agent particles themselves.
Ultrasound contrast agents produce unique acoustic signatures that allow to separate their signal from tissue echoes and to depict whether they are moving or stationary. This enables the detection of capillary flow and of targeted microbubbles that are retained in tissues such as normal liver.
The new generation of contrast media is characterized by prolonged persistence in the vascular bed which provides consistent enhancement of the arterial Doppler signal. Contrast agents make it also possible to perform dynamic and perfusion studies. Targeted contrast imaging agents are for example taken up by the phagocytic cell systems and thus have liver/spleen specific effects.

See also Ultrasound Contrast Agent Safety, Adverse Reaction, Tissue-Specific Ultrasound Contrast Agent, and Bubble Specific Imaging.

From Siemens Medical Systems;
We see a way to review 100% of your cardiovascular ultrasound exams and reports anywhere, anytime. The Cypress™ system is a highly miniaturized, all digital, phased array echocardiography system that provides complete studies and outstanding images - even on the most technically difficult patients.

Specifications for this system will be available soon.

From ESAOTE S.p.A.;
'The AU5 EPI is an ultrasound system for multi-disciplinary use that incorporates all the transducer technologies (linear, convex, phased array, and annular array) adapted to today's most diverse diagnostic requirements. Furthermore it offers the most modern and advanced techniques available today on the market.'

[This entry is marked for removal.]

'Acusphere (NASDAQ:ACUS) was a specialty pharmaceutical company that develops new drugs and improved formulations of existing drugs using its proprietary microparticle technology. Acusphere's three initial product candidates are designed to address large unmet clinical needs within cardiology, oncology and asthma. These product candidates were created using proprietary technology that enables Acusphere to control the porosity and size of nanoparticles and microparticles in a versatile manner that allows particles to be customized to address the delivery needs of a variety of drugs. Acusphere's lead product candidate, AI-700 (new trade name Imagify™), is a cardiovascular drug in Phase 3 clinical development. AI-700 is designed to enable ultrasound to compete more effectively with nuclear stress testing, the leading procedure for detecting coronary heart disease. An estimated 9.5 million procedures are done each year in the U.S. to detect coronary heart disease, the leading cause of death in the United States.'

In 2008 the FDA panel rejected the regulatory application for AI-700 (Imagify™) because of safety concerns.